MedPage Today on MSN7d
Rapid Improvement in Atopic Dermatitis With Dual JAK/TYK2 InhibitorMore than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 weeks of ...
Eczema is an umbrella term for a group of conditions that result in skin irritation and inflammation. The most common form of ...
A break from treatment with Vtama won’t lead to worsening of patients’ atopic dermatitis, finds a new analysis of an ...
A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat ...
Guttman-Yassky received research support, consulting, or lecture fees on atopic dermatitis from Regeneron, Sanofi, Pfizer, ...
Clinical trial results found that a majority of patients with atopic dermatitis who were treated with Ebgylss achieved ...
MedPage Today on MSN9d
T-Cell Rebalancing Therapy Active in Previously Treated Atopic DermatitisTreatment-emergent adverse events (TEAEs) occurred in a similar proportion of patients in each group, and were mostly mild or ...
ATOPIC dermatitis (AD) is a chronic inflammatory skin condition that significantly impacts patients’ quality of life. It is ...
The three-year study of Ebglyss saw an additional 83% of dermatitis patients achieving ‘almost clear’ skin using the single ...
New results show Eli Lilly (LLY) and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback